>
Switch to:

Allergy Therapeutics Debt-to-Equity

: 0.23 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $2.5 Mil. Allergy Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $13.2 Mil. Allergy Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $68.1 Mil. Allergy Therapeutics's debt to equity for the quarter that ended in Jun. 2021 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Allergy Therapeutics's Debt-to-Equity or its related term are showing as below:

OTCPK:AGYTF' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.29   Med: 0.11   Max: 5.78
Current: 0.23

-2.29
5.78

During the past 13 years, the highest Debt-to-Equity Ratio of Allergy Therapeutics was 5.78. The lowest was -2.29. And the median was 0.11.

OTCPK:AGYTF's Debt-to-Equity is ranked higher than
50% of the 933 Companies
in the Drug Manufacturers industry.

( Industry Median: 0.22 vs. OTCPK:AGYTF: 0.23 )

Allergy Therapeutics Debt-to-Equity Historical Data

The historical data trend for Allergy Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.07 0.28 0.23

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.21 0.28 0.20 0.23

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Debt-to-Equity falls into.



Allergy Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Allergy Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.4614305750351 + 13.207573632539) / 68.071528751753
=0.23

Allergy Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.4614305750351 + 13.207573632539) / 68.071528751753
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Allergy Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)